Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

Gary Kobinger works in a mobile laboratory installed by specialists of the National Public Health Agency of Canada in Mweka, Congo, Friday, Sept. 28, 2007.

Christopher Black/The Canadian Press

The scientist who led the work to develop the Ebola drug ZMapp is going to be leaving the National Microbiology Laboratory in Winnipeg.

Gary Kobinger is the lab's chief of special pathogens, heading a team that works on some of the world's worst disease threats.

Dr. Kobinger will be vacating that position next June to become the director of the Centre for Research in Infectious Diseases at Laval University in Quebec City.

Story continues below advertisement

"We're so proud. We consider we are very privileged to have the opportunity to have him," said Michel G. Bergeron, the founder and current head of the centre, who is relinquishing the directorship – but staying on as a researcher – after 41 years.

"Gary is a fantastic human being and an extraordinary researcher."

In an interview, Dr. Kobinger said the long notice will give the Public Health Agency of Canada time to find the right candidate to take over the special pathogens program, which has brought great acclaim to the national lab.

In addition to ZMapp, the Winnipeg group designed the first Ebola vaccine that has been shown to be effective in people. And it developed and pioneered use of small mobile laboratories – a lab in a suitcase, essentially – that have changed the way testing is done during Ebola outbreaks.

Dr. Kobinger grew up in Quebec and had hoped to return there some day. Still, he said deciding to step down from the Winnipeg job was difficult.

"It's actually very hard to leave here. … A very tough decision," said Dr. Kobinger, one of the world's leading Ebola researchers.

"The amount of publications and contributions that this group has been doing … in the past five years is quite impressive."

Story continues below advertisement

He has made many contributions to the field of research into viral hemorrhagic fevers such as Ebola and Marburg. But the development of the drug ZMapp will likely be remembered as one of his major contributions during his time in Winnipeg.

The drug is made up of three specific antibodies that fight Ebola. The drug is currently being tested in West Africa, though it is possible the dwindling outbreak there may end before the trial can be completed.

Immune systems produce a variety of antibodies to protect against disease invaders; some are general and some highly specific. To produce monoclonal antibody drugs such as ZMapp, scientists try to home in on specific antibodies, then clone them to produce concentrations of them to infuse into a sick person's bloodstream.

Dr. Kobinger and his team produced a cocktail of three Ebola monoclonals that looked promising against the virus in animal testing. Meanwhile, scientists at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Md., produced their own monoclonal cocktail of three antibodies. There was no overlap between the two.

Dr. Kobinger decided to try to optimize the cocktails, mixing and testing various combinations to see which was most effective when given to primates infected with Ebola. The resulting drug, ZMapp, is made up of two of Winnipeg's monoclonals and one made by the U.S. team.

Dr. Kobinger took over as special pathogens chief from the group's first head, Heinz Feldmann. Dr. Feldmann, who left the Winnipeg lab in 2008 to become chief scientist for Level 4 laboratories at the U.S. National Institute of Health's Rocky Mountain Laboratories in Hamilton, Mont., led the work on the Ebola vaccine.

Story continues below advertisement

Dr. Kobinger, who had been working on a different Ebola vaccine project at the University of Pennsylvania, had been collaborating with the Winnipeg group. Dr. Feldmann told then scientific director Frank Plummer he should hire Dr. Kobinger.

"So I hired him and it was one of the smartest things I ever did," Dr. Plummer said in an interview with The Canadian Press last year.

Over the past 15 months, Dr. Kobinger and 26 other scientists from the Winnipeg lab have worked in rotations in West Africa, with two- or three-person teams operating mobile laboratories to help Ebola treatment centres diagnose those infected with the disease. At one point, Winnipeg had three lab teams in the field. One team is still in Guinea.

Though Canada first developed a mobile testing lab, other countries have followed suit.

"I think the concept really spread out and I think that's awesome," Dr. Kobinger said.

At Laval, Dr. Kobinger will lead a centre with a strong reputation and a roster of 200 scientists.

Story continues below advertisement

It does not have a Level 4 laboratory. Those are the most secure laboratories, where work on the most dangerous pathogens is done. But Dr. Kobinger doesn't believe the move will spell the end of his Ebola work.

"I see this as expanding the horizons, not restricting them," he said.

"I have so many friends in the field of Level 4 [research] that I'm really hoping that I'll be able to keep collaborating with many of them."

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies